With positive Phase 2a results behind it and a Phase 2b study now underway, EnteroBiotix is advancing its lead microbiome therapeutic toward its next clinical milestone in irritable bowel syndrome (IBS).
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring EnteroBiotix and EBX-102-02®, an investigational oral therapy being developed for IBS-C.
The company’s RISE Phase 2b study is evaluating EBX-102-02 in approximately 300 patients, with topline efficacy data anticipated in H2 2027.
Why Investors Are Taking Notice
Clinical Momentum: Positive Phase 2a results followed by a 300-patient Phase 2b study.
Large Patient Population: IBS affects approximately 11% of the global population, with more than $10B in direct annual U.S. healthcare costs.
Recent Financing: EnteroBiotix raised £19M ($25M) to advance EBX-102-02 into Phase 2b.
Broader Pipeline: Additional microbiome programs are being developed in liver disease and blood cancer.
Hear more about EnteroBiotix’s clinical progress, upcoming milestones, and broader microbiome pipeline.
